Pipeline Previews

August 2015 | Volume 14 | Issue 8 | Features | 920 | Copyright © August 2015

Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.

Heliocare® Earns NSF Good Manufacturing Practice (GMP) Registration for IFC Manufacturing Facility GMP

Registration Demonstrates Ferndale Healthcare®’s Commitment to Quality

Ferndale Healthcare®, Inc. announced that the IFC manufacturing facility for its Heliocare® brand is now a Good Manufacturing Practices (GMP) facility registered by NSF International, a highly respected independent organization recognized as the world leader in standards development, product certification, education, and risk-management.
Earning GMP registration from NSF International verifies that IFC’s facility has the proper methods, equipment, facilities, and controls in place for producing dietary supplement products. NSF GMPs were developed in accordance with the U.S. Food and Drug Administration’s (FDA) 21 CFR part 111 regulations for the manufacturing, packaging, and distribution of dietary supplements. Utilizing GMP regulations assists companies in developing and maintaining proper controls in their manufacturing process so that products are processed, manufactured and labeled in a consistent manner, and meet quality standards.
Heliocare® is an oral dietary supplement with antioxidant properties that helps preserve the skin’s ability to protect itself against sun-related effects and aging.

FDA Approves Syneron Candela's PicoWay® Picosecond Laser for Treatment of Pigmented Lesions

The FDA has approved Syneron Candela’s PicoWay® picosecond laser for the treatment of pigmented lesions. The PicoWay® device previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the U.S. late in the fourth quarter 2014. Syneron Medical Ltd. also recently received Health Canada clearance of the PicoWay® picosecond laser for the treatment of pigmented lesions and tattoo removal.
PicoWay® is a dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay® technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos of all colors.